Equities
Health CareMedical Equipment and Services
  • Price (SEK)218.50
  • Today's Change-3.00 / -1.35%
  • Shares traded7.22k
  • 1 Year change+24.29%
  • Beta1.1098
Data delayed at least 15 minutes, as of Apr 17 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.

  • Revenue in SEK (TTM)677.29m
  • Net income in SEK130.31m
  • Incorporated1994
  • Employees228.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
C Rad AB424.60m46.00m1.28bn84.0028.704.6723.343.021.361.3612.558.341.144.453.82--12.415.8717.408.0645.4543.0110.865.602.48287.500.00640.0040.9117.43516.3916.82----
Sedana Medical AB (publ)153.87m-59.61m1.49bn83.00--1.53--9.67-0.6001-0.60011.559.760.14691.107.69---5.69-5.77-5.95-6.0870.8364.06-38.74-36.139.68--0.0044--25.2321.5918.90--42.12--
Stille AB294.89m26.65m1.63bn106.0034.171.4439.775.535.315.3158.76126.110.514----2,782,019.004.647.035.218.1944.8243.939.049.856.543.360.0021.9819.7016.78-2.485.3423.62--
ADDvise Group AB (publ)1.37bn103.50m1.64bn624.0023.293.997.711.190.55820.55827.393.260.52244.244.832,200,321.003.943.724.974.7765.4956.187.545.891.023.120.72460.940544.3038.6227.62--30.35--
Bactiguard Holding AB223.17m-138.38m2.20bn220.00--7.04--9.88-3.95-3.956.3710.080.30374.376.93---18.83-7.56-24.62-8.8127.4747.91-62.01-26.280.6445-8.670.3976---11.966.46-161.71--8.43--
Detection Technology Oyj-1.16tn-1.16tn2.39bn478.00--2.82----------4.97----------9.34--11.96--47.44--8.223.13--0.08153.455.292.027.55-18.03-14.88-9.55
BICO Group AB2.25bn-1.70bn2.93bn884.00--0.6132--1.30-23.61-27.6631.6069.180.24872.243.062,545,136.00-18.77---20.89--52.34---75.47--1.91-1.050.2852--6.09---1,889.33------
Medistim ASA525.26m103.61m3.40bn152.0032.788.5426.766.485.685.6828.7721.771.070.86465.983,462,921.0021.0122.9326.1428.5278.6778.2519.7220.642.61--0.042575.257.0010.06-8.9112.720.03314.87
CellaVision AB677.29m130.31m5.28bn228.0040.547.3731.067.805.465.4628.4030.040.74411.606.932,970,575.0014.3215.3016.6218.2468.3769.0319.2419.982.0159.030.0828110.185.9413.1710.128.0030.458.45
Revenio Group Oyj1.13bn221.29m8.03bn216.0035.896.8830.067.140.72050.72053.663.760.70695.507.60447,574.1013.9014.3316.7717.9051.0150.7319.6621.131.7928.490.152155.81-0.412525.80-12.1518.7217.676.30
Synsam AB (publ)5.91bn311.00m8.15bn3.41k26.023.207.721.382.092.0939.6216.960.73562.2213.121,730,149.003.86--5.27--75.50--5.25--0.4922--0.5675--11.90---5.18------
Xvivo Perfusion AB597.54m91.82m10.22bn160.00105.745.2667.3717.113.073.0719.9561.750.30421.236.203,734,638.004.671.235.021.3374.4973.1415.374.765.09--0.01590.0043.8826.04398.2948.5721.35--
Data as of Apr 17 2024. Currency figures normalised to CellaVision AB's reporting currency: Swedish Krona SEK

Institutional shareholders

33.46%Per cent of shares held by top holders
HolderShares% Held
SEB Investment Management ABas of 31 Aug 20232.00m8.38%
Swedbank Robur Fonder ABas of 29 Feb 20241.36m5.71%
Invesco Advisers, Inc.as of 31 Jul 20231.10m4.62%
Fj�rde AP-fondenas of 31 Dec 2023723.96k3.04%
Candriam Belgium SAas of 31 Jan 2024564.03k2.37%
AMF Fonder ABas of 31 Aug 2023555.78k2.33%
Handelsbanken Fonder ABas of 31 Mar 2024531.67k2.23%
Raiffeisen Kapitalanlage-Gesellschaft mbHas of 29 Feb 2024406.99k1.71%
Financi�re de l'�chiquier SAas of 30 Jun 2023374.98k1.57%
Harding Loevner LPas of 31 Dec 2023359.14k1.51%
More ▼
Data from 31 Dec 2023 - 29 Feb 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.